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Abstract: Central nervous system drug discovery and development is hindered by the impermeable
nature of the blood–brain barrier. Pharmacokinetic modeling can provide a novel approach to
estimate CNS drug exposure; however, existing models do not predict temporal drug concentrations
in distinct brain regions. A rat CNS physiologically based pharmacokinetic (PBPK) model was
developed, incorporating brain compartments for the frontal cortex (FC), hippocampus (HC),
“rest-of-brain” (ROB), and cerebrospinal fluid (CSF). Model predictions of FC and HC Cmax, tmax
and AUC were within 2-fold of that reported for carbamazepine and phenytoin. The inclusion
of a 30% coefficient of variation on regional brain tissue volumes, to assess the uncertainty of
regional brain compartments volumes on predicted concentrations, resulted in a minimal level of
sensitivity of model predictions. This model was subsequently extended to predict human brain
morphine concentrations, and predicted a ROB Cmax of 21.7± 6.41 ng/mL when compared to “better”
(10.1 ng/mL) or “worse” (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL
and a HC Cmax of 182.2 ± 51.2 ng/mL. These results indicate that this simplified regional brain
PBPK model is useful for forward prediction approaches in humans for estimating regional brain
drug concentrations.
Keywords: PBPK; pharmacokinetics; CNS; brain; blood–brain barrier; microdialysis
1. Introduction
Diseases of the central nervous system (CNS) present a considerable socioeconomic burden to
healthcare systems, and are expected to exponentially increase with an ageing population. The World
Health Organization (WHO) highlighted “brain diseases” as contributing to more than 35% of the
total disease burden in Europe [1]. However, the majority of CNS disorders that warrant effective
drug therapy currently lack examples of successful pharmacotherapy [2]. This failure is often related
to the difficulty of finding medicines that can cross the blood–brain barrier (BBB) and enter the
brain parenchyma [2]. The BBB plays a significant role in maintaining the neuroparenchymal
microenvironment by protecting neural tissues from toxins [3]. Furthermore, the BBB presents
an almost impermeable barrier to drug delivery for most small molecular weight compounds,
thus often contributing to the attrition of many CNS drug development programs [2,4]. The ability
to pragmatically assess the extent of CNS drug disposition in early discovery/development phases
may potentially assist with understanding the characteristics of CNS uptake, and reduce the need for
complex in vivo procedures to quantify CNS drug disposition. Traditional approaches to tackle this
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have often focused on determining the steady-state brain distribution of drugs in preclinical species,
referred to as the brain-to-plasma ratio or Kpbrain, and correlating this to the molecular properties
in order to model/extrapolate brain distribution [5,6]. To account for the driving force for brain
delivery (i.e., membrane permeability) and target site receptor occupancies, this is often corrected for
the unbound brain-to-unbound plasma ratio (Kpuu,brain) [7,8].
There is, however, a significant lack of mechanistic predictive models capable of quantifying
CNS drug disposition, particularly in different brain and CNS regions. In non-physiological empirical
pharmacokinetic models, the CNS is described by either a one-compartment model (representing the
brain) or a two-compartment model (representing brain interstitial fluid and brain intravascular fluid
(IVF)), with such models often being used in conjunction with brain microdialysis data to describe
CNS drug disposition [9,10]. Semi-physiological models have also been proposed in an attempt to
describe drug disposition within the brain mechanistically [11–19].
However, all current semi-physiological and non-physiological models employed to describe
CNS pharmacokinetics fail to consider regional CNS pharmacokinetics within district brain sections,
which limits the application of such models to the assessment of regional brain extracellular fluid
(ECF) drug disposition.
Recently, a series of publications by Yamamoto et al. [20–23] have established the basis for
mechanistic regional pharmacokinetic modeling of CNS tissues; however, these models are based on
a global regional model of the CNS (i.e., inclusion of regional CSF compartments), which would be
more applicable to clinical sampling in humans (i.e., spinal CSF). Furthermore, such models were
developed using population-based compartment modeling pharmacokinetics (e.g., NONMEM [24]).
To address this limitation, PBPK can be used to mechanistically describe the drug concentration in
tissues with consideration of regional drug brain tissue distribution [25,26]. A key benefit of the
application of PBPK models is the ability to amalgamate existing relevant physiological processes,
which may impact on the pharmacokinetics of compounds alongside a compound’s physicochemical
properties to mechanistically describe a compound’s pharmacokinetics and allow both interspecies
scaling and the prediction of whole organ and organ sub-compartment temporal concentration profiles.
As opposed to empirical models, an integration between system-dependent (physiological) and
compound-dependent parameters of PBPK models in predicting the compound’s PK profile has
enabled an understanding of the underlying mechanisms of the PK [11,27] and recently been applied
to model ECF pharmacokinetics of drugs [28–30].
The need for quantifying regional brain temporal concentrations is integral to expanding existing
CNS PBPK modeling approaches, particularly for those drugs that are reported to be unevenly
distributed within the brain [31,32]. The aim of this study is therefore to develop a PBPK model of
the rat CNS that considers the whole brain ECF in addition to two regional compartments, namely
the frontal cortex and hippocampus, to predict regional brain pharmacokinetics of phenytoin [31]
and carbamazepine [33]. Furthermore, the model was expanded to predict the human regional brain
pharmacokinetics of morphine.
2. Materials and Methods
A three-stage workflow methodology was applied to model development. Step 1 focused on the
validation of a whole-body PBPK model incorporating a previously published CNS PBPK model [28],
for the prediction of Kpuu,brain for 10 passively transported compound. Step 2 adapted this CNS PBPK
model to include two regional brain compartments, namely the frontal cortex and hippocampus,
and validated these against two reported studies of phenytoin [31] and carbamazepine [33] regional
brain ECF temporal concentration from rodent microdialysis studies. Subsequently, Step 3 extrapolated
the regional brain PBPK model to humans for the prediction of morphine pharmacokinetics based on
reports of human brain microdialysis of morphine [34,35].
Pharmaceutics 2018, 10, 14 3 of 18
2.1. Step 1: A Whole-Body Physiologically Based Pharmacokinetic (PBPK) CNS Model
A whole-body PBPK model was developed in MATLAB 9.1 (The MathWorks, Inc., Natick, MA,
USA) [36]. The model incorporated the following compartments: lung, heart, brain, muscle, adipose,
skin, spleen, liver, pancreas, gut, stomach, bone, kidney, arterial blood, and venous blood. All tissue
compartments were modeled as well-stirred (Figure 1).
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compartments, except CNS tissues, assumed as perfusion-limited/well-stirred and are fully described 
in the Supplementary Materials (Equation (S1)). 
Drug removal from eliminating organs (liver and kidney) was described by either a hepatic 
clearance (CLH) or renal clearance (CLR) term. Hepatic clearance was derived from either in vitro 
intrinsic metabolic clearance (CLint, in vitro) or in vivo human blood or plasma clearance (CLb or CLp). 
Renal clearance was calculated using a GFR (glomerular filtration rate) correction approach [37]. 
Intrinsic clearance was scaled to a CLH, through the use of microsomal recovery (microsomal 
protein content: 45 mg protein/g liver) or hepatocellularity (130 × 106 cells/g liver) and assuming a rat 
liver weight of 40 g/kg body weight [38–40], before being scaled using a well-stirred liver model 
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Figure 1. A generic whole-body PB K model. Arrows indicated direct on of bl od flow. Q: blood flow;
CLH: hepatic clearanc ; CLR: renal clearance.
Ordinary differential equations were used to describe the whole-body PBPK model with all
compartments, except CNS tissues, assumed as perfusion-limited/well-stirred and are fully described
in the Supplementary Materials (Equation (S1)).
Drug removal from eliminating organs (liver and kidney) was described by either a hepatic
clearance (CLH) or renal clearance (CLR) term. Hepatic clearance was derived from either in vitro
intrinsic metabolic clearance (CLint, in vitro) or in vivo human blood or plasma clearance (CLb or CLp).
Renal clearance was calculated using a GFR (glomerular filtration rate) correction approach [37].
Intrinsic clearance was scaled to a CLH, through the use of microsomal recovery (microsomal
protein content: 45 mg protein/g liver) or hepatocellularity (130 × 106 cells/g liver) and assuming a
rat liver weight of 40 g/kg body weight [38–40], before being scaled using a well-stirred liver model
(Equation (1)):
CLH =
fup ×CLint, in vivo ×QL
QL + fup ×CLint, in vivo/Rb
(1)
Tissue volumes and blood flow rates were obtained from the published literature [11,41] (Table 1).
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Table 1. System-related parameters used for the rat whole-body PBPK model.
Tissue
Perfusion Volume
Rat Human Rat Human
(mL/min) (mL/min) (mL) (mL)
Adipose 4.72 277.5 19.03 10,725
Bone 8.08 270 10.37 9300
Brain 1.12 750 1.43 1552.5
Gut 12 975 6.75 1770
Heart 3.2 160.5 0.825 285
Kidney 11.6 1177.5 1.825 330
Liver 20 1575 10.3 1807.5
Lungs 80 5325 1.25 1252.5
Muscle 18.96 802.5 101 32,175
Pancreas 1 142.5 1.3 90
Skin 4.08 322.5 47.5 8325
Spleen 0.88 82.5 0.5 202.5
Arterial blood - - 6.8 1927.5
Venous blood - - 13.6 3855
Ten passively transported compounds (benzylpenicillin, buspirone, caffeine, carbamazepine,
diazepam, midazolam, phenytoin, sertraline, thiopental, and zolpidem) with reported unbound
brain:unbound plasma partition coefficient (Kpuu,brain) were selected to validate the structure
of the PBPK model. Physicochemical data for compounds are detailed in the Supplementary
Materials (Section 1.1, Tables S1–S5). This approach required prediction of both plasma and brain
concentration-time profiles to calculate the Kpbrain (brain-to-plasma partition coefficient) (Equation (2))
and more specifically when corrected for the unbound fraction, Kpuu,brain (Equation (3)):
Kpbrain =
Cbrain
Cplasma
(2)
Kpuu,brain =
∫ ∞
0 Cubrain× dt∫ ∞
0 Cuplasma× dt
=
AUCu,brain
AUCu,plasma
(3)
The brain was modeled with a perfusion-limited compartment (see Supplementary Materials
Figure S1). Absorption (permeability clearances) from the BBB, protein binding (plasma, brain
tissue and CSF), metabolic clearance and predicted tissue partition coefficients (Kpt) were previously
collated by our group [28] and implemented within the model as described by Equation (S2) in the
Supplementary Materials. In this approach, in vitro permeability was scaled to in vivo permeability
through correction for the brain microvascular endothelial surface area (150 cm2·g·brain−1 for rats [42]
or 157 cm2·g·brain−1 [43] for humans) and was parameterized into the appropriate unidirectional PS
term (Equations (4) and (5)):
PSblood−to−brain direction = PappAB × Brain weight× Surface Area×CF (4)
PSbrain−to−blood direction = PappBA × Brain weight× Surface Area×CF (5)
where brain weight was assumed to be 1.8 g in rats, 0.36 g in mice, and 1500 g in humans [44–46].
The CF term relates to an in vitro to in vivo extrapolation factor that corrects for the absent
physiological conditions inherent in the determination of the in vitro permeability [29,30]. It is also
important to note that, for actively transported compounds, CF can be replaced by a relative expression
factor (REF) that accounts for the differences in transporter abundances from the in vitro system to
the in vivo species being studied [29,30]. CF was assumed to be “1” in the absence of any parameter
estimation approaches. When only a single Papp was reported in the literature, the resultant predicted
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PS was assumed to be bidirectional. Furthermore, for active efflux compounds, the PSblood-to-brain was
assumed to be bidirectional and the active efflux component was applied through correction of the
PSbrain-to-blood of the efflux ratio of the substrate [28].
All compounds were simulated using IV bolus doses.
The validity of individual compounds was assessed using a fold-error (FE) method whereby
whenever the observed Kpuu,brain values were determined to be more than the predicted
Kpuu,brain values,
FE =
Kpuu,brainObserved
Kpuu,brainPredicted
(6)
If however, the predicted Kpuu,brain values were more than the observed Kpuu,brain values,
FE =
Kpuu,brainPredicted
Kpuu,brainObserved
(7)
2.2. Step 2: Development of a Rat Regional Brain PBPK Sub-Model
A study by Walker et al. (1996) [31] reported the regional brain concentration of phenytoin
in distinct brain regions of the rat, namely the hippocampus and frontal cortex. A further study
by Van Belle et al. (1995) [33] also reported carbamazepine regional brain concentrations in
the hippocampus. These studies were used to validate the regional brain PBPK sub-model.
Compound-specific parameters for phenytoin and carbamazepine, along with permeability clearances
across the hippocampus, frontal cortex, and the rest of the brain tissues were obtained from previously
collated in vitro permeability data [28].
Model development adapted a previously reported CNS PBPK model [28] to include a
hippocampus and frontal cortex compartment (Figure 2) and was applied to the whole-body PBPK
model, with systems parameters detailed in Table 2.
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In the development of this model, the following assumptions are made: 
1. The CNS is represented by five compartments, namely CSF, intracranial blood, rest of brain 
tissue, frontal cortex, and hippocampus; 
2. All compartments are well stirred, with permeability barriers between the intracranial blood and 
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3. There is no rate-limiting diffusion barrier between the ECF and CSF, and the drug equilibration 
between these two compartments is rapid [29]; 
4. Only an unbound drug, governed by unbound fraction in plasma (fu,plasma), brain tissue (fu,brain) 
or CSF (fu,CSF), was considered capable of crossing permeability barriers; 
5. In the absence of published regional fu,brain, the unbound brain fraction was assumed to be 
equivalent for all brain regions (i.e., hippocampus, rest of brain, and frontal cortex) [47]; 
6. Within the extracellular space of the brain, fluids move either by diffusion or by bulk flow (Qbulk) [48]; 
Figure 2. Five-compartmental rat CNS PBPK brain model. Q: blood flow; PS: permeability surface-area;
BB: intracranial blood; HC: hippocampus; FC: frontal cortex; C and CSF: cerebrospinal fluid; BT: brain
tissue; fu: drug fraction unbound in brain regions (fu,brain), CSF (fu,CSF) or plasma (fu,plasma).
In the development of this model, the following assumptions are made:
1. The CNS is represented by five compartments, namely CSF, intracranial blood, rest of brain tissue,
frontal cortex, and hippocampus;
2. All compartments are well stirred, with permeability barriers between the intracranial blood
and brain;
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3. There is no rate-limiting diffusion barrier between the ECF and CSF, and the drug equilibration
between these two compartments is rapid [29];
4. Only an unbound drug, governed by unbound fraction in plasma (fu,plasma), brain tissue (fu,brain)
or CSF (fu,CSF), was considered capable of crossing permeability barriers;
5. In the absence of published regional fu,brain, the unbound brain fraction was assumed to be
equivalent for all brain regions (i.e., hippocampus, rest of brain, and frontal cortex) [47];
6. Within the extracellular space of the brain, fluids move either by diffusion or by bulk flow
(Qbulk) [48];
7. Where absent from the literature, hippocampus and frontal cortex volumes scaled from mice to
rats based on brain weight ratio-scalars [28,45,46,49];
8. Due to the absence of regional brain in vitro or in vivo permeability data, the regional brain
bi-directional passive transport (PS) term was scaled from in vitro Papp and corrected for the
regional tissue weight (Table 2, assuming density = 1) using Equations (4) and (5), wherein the
term “brain weight” is replaced by “regional brain weight”;
9. The temporal concentration profile of the drug in the regional brain ECF would mimic the
biophase sampled during microdialysis studies [50];
10. Since the liver was considered the only site of clearance for phenytoin based on the literature [51],
the prediction for unbound renal clearance (CLR) was excluded from the simulation;
11. Active transport from brain tissues (Efflux: CLBout; Influx: CLBin) can be determined as described
in our previous CNS PBPK model [28].
Table 2. System-related parameters used for the brain PBPK model.
Rat Human
Flow Rates a Q (mL/min)
Rest of brain tissue to CSF (bulk flow) 0.00024 0.285
Hippocampus to CSF (bulk flow) 0.00002 0.00114
Frontal cortex to CSF (bulk flow) 0.00005 0.0566
CSF production rate 0.0037 b 0.35 c
CSF absorption (Qcsink) d 0.0037 0.35
Volume V (mL)
Intercranial blood e 0.025 75
Rest of brain tissue f 1.222 1211
* Rest of brain tissue ECF e 0.243 267
Hippocampus 0.093 g 5.68 h
* Hippocampus ECF e 0.019 1.07
Frontal cortex 0.233 i 283 j
* Frontal cortex ECF e 0.038 53.2
CSF 0.25 k 160 l
* Monte Carlo simulations were applied to address uncertainty in true parameter value. A 30% CV was applied
as the boundary conditions and predictions conducted with all parameters identified simultaneously using a
log-normal distribution with at least 3000 iterations per compound. a Regional brain ISF bulk flow was assumed to
be 0.2 µL/min·g brain [52] and assumed to be species independent; b Taken from Harnish et al. [53]; c Taken from
Brinker et al. [54]; d Assuming that the rate of CSF absorption is the same with CSF production rate [55]; e Calculated
by assuming fractional volume of brain intravascular fluid is 0.014 and fractional volume of brain interstitial space
0.188 [56]; f Assumes average brain weight of 1.8 g in rats, 0.36 g in mice and 1500 g in humans [44–46]; g Taken
from Lee et al. [57]; h Taken as mean of total hippocampal volume (right and left) [58]; i Scaled based on a
mean mouse frontal cortex volume of 0.0467 mL [59] and a scalar of 5 (ratio of rat brain weight:mouse brain
weight) or 4166 (ratio of human brain weight:mouse brain weight); j Taken as mean of range reported values from
Semendeferi et al. [60]; k Taken from Bass and Lundbord [61]; l Taken from Sakka et al. [62].
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The CNS PBPK model equations are detailed in the Supplementary Materials (Section 2,
Equations (S3)–(S6)), with compound physicochemical data detailed in the Supplementary Materials
(Section 2.1, Table S6).
For the rat brain PBPK model, the tissue volumes and blood flow rates were obtained from
the published literature (Table 2). Subsequently, the five-compartment brain model was applied to
predict plasma, rest of brain, hippocampus, and frontal cortex concentration profiles following an
intraperitoneal dose of 50 mg/kg of phenytoin [31] or a 10-mg IV infusion (10 min) of carbamazepine.
In order to account for the uncertainty in the ECF volumes of regional brain compartment,
Monte Carlo simulations were used to incorporate a 30% CV (log-normal distributed) on the fixed
estimates of ECF compartment volumes (simultaneous applied and simulated to the rest of brain,
hippocampus and frontal cortex) resulting in at least 3000 runs per compound (1000-per compartment).
This was applied using simulations for both rat (Step 2) and human (Step 3) models. The resultant 5th
and 95th percentiles were graphically assessed.
To assess the impact of PS parameter uncertainty on model predictions, a sensitivity analysis was
conducted to assess the impact of variation in PSHC_BT and PSBB_HC and PSFC_BT and PSBB_FC, on the
hippocampus and frontal cortex Cmax over a PS range of 0.01 to 100 mL/min using phenytoin as a
model compound. Three-dimensional mesh plots were used to assess this relationship graphically.
2.3. Step 3: Development of a Human Regional Brain PBPK Sub-Model
To explore the possibility of utilizing the regional brain PBPK model to predict human brain
pharmacokinetics, human CNS physiological parameters were used to develop a human regional CNS
PBPK model (Table 2) based upon the regional brain model described in Section 2.2. Despite limited
human brain concentration data being reported in the literature, two studies were chosen that reported
morphine brain concentrations in patients who suffered from traumatic brain injury, acquired using
microdialysis cerebral catheter insertion in “better” or “worse” brain tissues, as determined by
computed tomography scanning [34,35]. Systems parameters for the human CNS PBPK model are
detailed in Table 2 and morphine-specific parameters are detailed in the Supplementary Materials
(Section 2.1, Table S6).
3. Results
3.1. Step 1: Validation of the PBPK Model
To develop a broader regional CNS PBPK model, this step focused upon the development of a
base PBPK model consisting of a whole-body PBPK incorporating a simplistic 1-compartment model
of the brain. Predictions of brain temporal concentration profiles were surmised using the unbound
brain: plasma ratio (Kpuu,brain), which is widely used to assessed brain drug partitioning. Validation
of the WB-PBPK examined the ability of the model to predict Kpuu,brain in rats for 10 compounds
demonstrating passive absorption across the BBB that were previously used in PBPK modeling by our
group [28]. The WB-PBPK model was capable of predicting Kpuu,brain to within 5-fold of the reported
Kpuu,brain for all compounds except benzylpenicillin, which was 5.34-fold over predicted (Figure 3).
3.2. Step 2: Development of a Rat Regional Brain PBPK Sub-Model
3.2.1. Case 1: Phenyotin
The base PBPK model described in Step 1 was adapted to replace the one-compartment brain
model with a five-compartment regional brain model. This model was then used to predict phenytoin
plasma and regional brain concentrations.
Predictions of phenytoin plasma concentration profiles were subsequently simulated and found
to be within the range of observed profiles (Figure 4), with a predicted Cmax (61.79 µmol/L) similar
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to that reported by Walker et al. (1996) [31], 61.69 ± 4.7 µmol/L. Furthermore, a similar tmax was
predicted compared to that reported by Walker et al. [31], approximately 20 min (Figure 4).
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as reported by Walker et al. (1996) [31] and were generally in agreement with observed profiles in each
brain region (Figure 5).
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Model predicted Cmax and AUC were within 2-fold of that reported [31] (Table 3). Predictions of
hippocampus tmax, approximately 20 min, were slightly over-predicted compared to the observed tmax
of 15 min. For the frontal cortex mean concentration, Cmax was predicted at 3.87 ± 0.24 µmol/L and
was consistent with the published literature Cmax of 3.98 ± 1.1 µmol/L (Figure 5B).
Table 3. Summary of predicted and observed pharmacokinetic parameters of phenytoin in plasma,
hippocampus and frontal cortex in rats.
Plasma Hippocampus Frontal Cortex
Cmax AUC Cmax AUC Cmax AUC
(µmol/L) (µmol/L·min) (µmol/L) (µmol/L·min) (µmol/L) (µmol/L·min)
Predicted 61.79 5891.97 8.62 ± 3.42 718.29 ± 18.31 3.87 ± 0.24 340.47 ± 11.53
Observed 61.69 ± 4.7 5924.55 ± 340.4 7.00 ± 2.2 594.74 ± 21.2 3.98 ± 1.1 370.97 ± 17.1
AUC is calculated as AUC(0-last); Data represents mean ± SEM.
In both cases, the afe and rmse of 0.92 and 0.40 respectively, were indicative of good model
prediction. Furthermore, predictions of the regional Kpuu,brain for the hippocampus (0.12) and frontal
cortex (0.057) were within 2-fold of the reported regional Kpuu,brain of 0.11 for the hippocampus and
0.08 for the frontal cortex.
3.2.2. Case 2: Carbamazepine
Predictions of carbamazepine plasma concentration profiles were found to be within the range
of the observed data (Figure 6A), with a predicted Cmax (1.81 nmol/mL) similar to that reported by
Van Belle et al. (1996) [33], 2.14 ± 0.27 nmol/mL (Table 4). Furthermore, a similar tmax was predicted,
39 min, compared to the reported tmax [33] of approximately 44 ± 9 min (Table 4).
Van Belle et al. [33] reported carbamazepine hippocampus pharmacokinetics following a single
dose to rats and this was used as a basis to further validate the regional brain PBPK model. The model
predicted plasma (Figure 6A) and hippocampus (Figure 6B) Cmax and AUC to within 2-fold of the
reported values (Table 4). Furthermore, predicted regional Kpuu,brain were within 2-fold of the reported
Kpuu,brain (reconstructed from the AUC ratios) [33], 0.79 and 1.02 respectively.
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Table 4. Summary of predicted and observed pharmacokinetic parameters of carbamazepine in plasma
and hippocampus brain regions in rats.
Plasma Hippocampus Frontal Cortex
Cmax AUC Cmax AUC Cmax AUC
(µmol/L) (µmol/L·min) (µmol/L) (µmol/L·min) (µmol/L) (µmol/L·min)
Predicted 61.79 5891.97 8.62 ± 3.42 718.29 ± 18.31 3.87 ± 0.24 340.47 ± 11.53
Observed 61.69 ± 4.7 5924.55 ± 340.4 7.00 ± 2.2 594.74 ± 21.2 3.98 ± 1.1 370.97 ± 17.1
Data represents mean ± SD.
3.2.3. Model Sensitivity Analysis
To assess the impact of parameter uncertainty on model predictions, a sensitivity analysis
assessed the impact of variation in PSHC_BT, PSBB_HC, PSFC_BT and PSBB_FC on phenytoin (as a model
compound) hippocampus and frontal cortex Cmax over a PS range of 0.01 to 100 mL/min (Figure 7).
Model predictions were generally sensitive to changes in both drug flux into each compartment
(PSBBB_HC or PSBBB_FC) and out of each compartment (PSHC_BT or PSFC_BT). Irrespective of changes
in hippocampus PS over the range simulated, predicted Cmax spanned 3.7 to 8 µM. Furthermore,
variations in frontal cortex PS resulted in a predicted Cmax spanned 2.3 to 3.9 µM. Assuming regional
differences in the HC and FC compared to the rest of the brain, where flux across the regional BBB
located at the “rest of brain” was ten-folder greater than that of the HC or FC, limited sensitivity was
simulated across any change in PSBBB_HC, PSBBB_FC, PSHC_BT or PSFC_BT.
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Figure 7. Model sensitivity analysis of brain PS on Cmax. Sensitivity analysis of the impact of variation
in PS on the hippocampus (upper panel) or frontal cortex (lower panel) phenytoin Cmax. Gray mesh
indicates profiles where PSBBB_BT is 10-fold lower and pink mesh indicates profiles where PSBBB_BT
is 10-fold higher than that presented in the associated multicolor mesh plots. PS: permeability
surface area product; HC_BT (hi pocampus and brain tissue); BBB_HC (cerebral microvasculature
[blood brain barrier] and hippoc mpus); FC_BT (frontal cortex and brain tissue) and BBB_FC
(cerebral microvasculature [blood brain barrier] and frontal cortex).
3.3. Step 3: Development of a Human Regional Brain PBPK Sub-Model
In an attempt to predict regional brain concentrations in humans, we utilized data reporting
morphine brain concentrations in patients who suffered from traumatic brain injury using microdialysis
cerebral catheter insertion in “better” or “worse” brain tissues, as determined by computed tomography
scanning [34,35].
The plasma concentration–time profile was well predicted (Figure 8A) with Cmax, tmax and
AUC all within 2-fold of the reported values (Table 5). In the absence of human hippocampus or
frontal cortex temporal concentration profiles, we compared the reported profiles for “better” and
“worse” brain morphine temporal concentration profiles to those generated within the “rest of brain”
compartment within the regional brain PBPK model (Figure 8B). The model predicted a ROB Cmax of
14.5 ± 4.21 ng/mL, which was within the range reported for both “better” and “worse” brain tissue,
in addition to calculated AUC beings within 2-fold of those reported (Table 5). However, tmax was
2.5-fold underpredicted. For regional brain compartments, the hippocampus exhibited a slow transfer
of morphine leading to a tmax of 79.6 min and Cmax of 124.4 ± 41.2 ng/mL, while the frontal cortex
tmax was shorter (26.5 min) with a Cmax of 38.91 ± 15.78 ng/mL (Figure 8C,D).
Table 5. Summary of predicted and observed pharmacokinetic parameters of morphine in plasma and
regional brain compartments in humans.
Compartment Cmax AUC tmax
(ng/mL) (ng/mL·min) (min)
Plasma
Predicted 208.2 5363 7.2
Observed 178 7513 ± 124 9.8
Better Brain Observed 10.1 941.7 31.4 ± 17.1
Worse Brain Observed 29.8 2732 17.8 ± 2.3
Rest of brain Predicted 14.5 ± 4.21 815 ± 93 18.1
Hippocampus Predicted 124.4 ± 41.2 19,971 ± 3791 79.6
Frontal Cortex Predicted 38.9 ± 15.7 2444 ± 153 26.5
Data represents mean ± SD.
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4. Discussion
Central nervous system (CNS) disorders affect millions of people worldwide despite the
availability of a wide range of established treatments [1]. The primary challenge to CNS drug delivery
is the penetration of the blood–brain barrier in order to attain a sufficiently high biophase concentration
for a clinical effect. Given the lengthy discovery and development times associated with CNS drug
development, the application of mechanistic pharmacokinetic modeling has emerged to bridge the
gaps between in vivo and in vitro approaches to expedite extrapolation of the pharmacokinetics of
drug compounds and to aid in the selection of appropriate doses for clinical studies [63,64].
The primary aim of this research was to employ mechanistic pharmacokinetic modeling
approaches to develop models capable of conducting robust in vitro to in vivo correlation and
thus allow interspecies extrapolations (rodent to human). Such approaches are based around a
mechanistic set of physiological (“systems”) parameters describing the physiology of the model system
(e.g., rodents or humans) and in vitro derived or estimated drug (“compound”) parameters.
Such extrapolations will enable the quantification and prediction of the extent of drug delivery
to the brain and wider CNS across drug barrier sites, namely, the BBB and the regional brain area.
These mechanistic platforms are in line with a replacement, reduction and refinement concept that is
integrated into the drug discovery framework [65]. The aim of this study was therefore to develop a
PBPK model of the rat CNS that considered the whole brain ECF in addition to the frontal cortex and
hippocampus, to predict regional brain pharmacokinetics of phenytoin and carbamazepine in rats,
in addition to the prediction of human regional brain pharmacokinetics or morphine.
4.1. Validation of the PBPK Model
To develop an accurate brain PBPK model that can predict human drug concentrations from a
limited set of routinely available pre-clinical and in vitro drug-specific parameters, a robust validation
process is essential to determine the prediction accuracy and precision. A rat CNS PBPK model
developed by Ball et al. (2012) [30] was selected to confirm successful base model development.
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Initial validation was conducted by comparing the Kpuu,brain values between the predicted and
published data for passively transported compounds, namely benzylpenicillin, buspirone, caffeine,
carbamazepine, diazepam, midazolam, phenytoin, sertraline, thiopental, and zolpidem [28].
Model predictions were all within 5-fold of the observed Kpuu,brain, with prediction of Kpuu,brain for
benzylpenicillin being 5.5-fold overpredicted (Figure 3). This overprediction found in benzylpenicillin
may be a result of the involvement of unclarified molecular active transport mechanism through the
BBB, as reported by Suzuki et al. [66,67], where the rapid CNS elimination was not captured during
the simulation.
As the description of the brain compartment using a simplistic permeability limited compartment
is not physiologically relevant, it would be expected that model predictions of temporal brain
concentrations would, therefore, be less accurate and this would account for the large error range
simulated. This basic CNS PBPK model was subsequently adapted and built upon in Step 2 to propose
a regional brain CNS PBPK model that was more mechanistically derived.
4.2. Prediction of Regional Brain Concentrations in Rats
In order to expand upon this previously developed model, we adapted the basic CNS
PBPK model to include two further tissue compartments, namely the frontal cortex and
hippocampus. In this process, we identified two candidate compounds to validate our adapted
model against, phenytoin and carbamazepine. Both compounds have been administered to rats and
region-specific brain microdialysis conducted to assess the CNS pharmacokinetics. Frontal cortex and
hippocampus phenytoin concentrations had been previously reported by Walker et al. (1996) [31],
with Van Belle et al. (1995) [33] also reporting carbamazepine regional brain concentration in the
hippocampus. The PBPK model incorporated an in situ permeability surface area (PS) previously
reported in rodents to drive diffusion from the plasma circulation into the CNS. The resultant
predictions of plasma and regional concentrations were within the range of concentrations reported for
both compounds (Figures 4–6), with the majority of model predictions pharmacokinetic parameters
within 2-fold of that observed (Tables 4 and 5).
Model Sensitivity Analysis
Monte-Carlo based model sensitivity analysis was first addressed by assessing the uncertainty in
our calculation of regional brain compartments volumes on predictions of regional brain concentrations.
The resulting prediction range (5th–95th percentiles) adequately spanned a similar range to the
reported range in the observed datasets from both Walker et al. (1996) [31] (Figure 5) and
Van Belle et al. (1995) [33] (Figure 6) and highlights the importance of the potential inter-individual
variability in regional brain tissue volume on overall model predictions.
Assuming the permeation of drug across the brain microvascular is uniform (i.e., no regional
differences), variations in the inter-regional brain permeability (PSHC_BT or PSFC_BT) of the drug would
play a minimal role in influencing regional brain Cmax. Furthermore, assuming that the regional
brain penetration of drug was non-uniform across the brain, a 10-fold lower or 10-fold higher shift in
PSBBB_BT would significantly increase (10-fold lower) or reduce (10-fold higher) overall regional brain
Cmax (Figure 7).
4.3. Prediction of Regional Brain Concentrations in Humans
The prediction of human CNS pharmacokinetics, from preclinical data, would provide an
invaluable approach to assessing the usefulness of candidate molecules progressing through the
drug development process.
Human brain pharmacokinetics data is extremely sparse in the literature; a study was selected
that applied microdialysis to quantify morphine pharmacokinetics in human brain tissue, where a
relatively rich brain pharmacokinetic profile was available. These data were available for “brain tissue”,
and we assumed this was equivalent to the “rest of brain” compartment within our five-compartment
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brain model. The resultant model predictions resulted in a reasonable prediction of the shape of the
concentration profiles along with a good estimate of the Cmax and AUC, the former of which was
predicted within the “range” of “better” and “worse” Cmax reported in the observed datasets (Figure 8).
However, the prediction of the terminal elimination phase was poorer than expected, although the
reported data only illustrated data points for two representative patients, the distribution of resultant
morphine concentrations at each time point was not reported and hence we were unable to ascertain
the intra-individual variability.
As a first principles approach, we have been able to capture the pharmacokinetics of morphine
in human brain tissue and the validated “rest of brain” compartment. Assuming PS is scaled from
in vitro Papp based on correction for surface area (cm2/g tissue), the PS would be “corrected” for
overall surface area based on the gross tissue weight. Furthermore, the small regional mass of the
hippocampus would result in a highly localized concentration of morphine, which would slowly
diffuse out of the brain tissue as a result of the smaller surface area. Similarly, regional differences in
both morphine [68] and biperiden have been reported in rat brains and biperiden [69].
Further although this model did not consider active transport substrates, it would be possible
to model the active transport of, for example P-glycoprotein substrates. This is made possible by
the availability of absolute protein abundance data for a range of transporter proteins at brain
barriers as a result of the application of quantitative proteomics [70,71]. Furthermore, we have
previously demonstrated the application of this approach to the prediction of Kpuubrain (for whole
brain) for 11 active transporter substrates using a similar CNS PBPK [28], where an active transport
permeability surface area (PS) can be determined by the use of a corrected efflux ratio (to account for the
differentiation between purely active and purely passive transport) [72,73] in addition to accounting
for the abundance of the transporter protein in question factor [28].
Finally, key to driving regional brain drug concentration predictions would be accounting for
any potential regional differences in non-specific brain tissue binding (i.e., a brain regional specific
fubt). In the absence of any reported regional brain fubt data, we assumed fubt was uniform across all
brain regions. Any regional differences in grey/white matter phospholipid /lipid content may result
in localized differences in fubt. Indeed, it has been reported that differences in lipid content do exist
when comparing white and grey matter regions [74–77]. Given these potential regional differences in
brain composition, the application of techniques such as equilibrium dialysis should be encouraged to
further investigate and determine fubt for specific brain regions to provide more appropriate input
data in the model.
5. Conclusions
A regional brain PBPK model was developed for rats and extended to model the human regional
brain pharmacokinetics of morphine. While the limiting factor in the application of this model
to human CNS pharmacokinetics is the paucity in human brain (whole) or regional brain drug
concentrations, with the greater application of cranial microdialysis it would be possible to further
refine the proposed model for application in regional brain concentration. Nonetheless, the manuscript
has successfully proposed a simplified first principles approach to the development of a regional brain
CNS PBPK model.
Supplementary Materials: Supplementary materials can be found online at the following link www.mdpi.
com/1999-4923/10/1/14/s1. The regional brain PBPK model has been provided as a ‘systems-biology markup
language’ (SBML) file in an extended markup language format (.xml) format.
Acknowledgments: The authors would like to thank the Ministry of Health Malaysia for providing funding for
this project.
Author Contributions: Zaril Zakaria and Raj Badhan conceived and designed the experiments; Zaril Zakaria
performed the experiments; Zaril Zakaria and Raj Badhan analyzed the data; Zaril Zakaria wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
Pharmaceutics 2018, 10, 14 15 of 18
References
1. Olesen, J.; Baker, M.G.; Freund, T.; di Luca, M.; Mendlewicz, J.; Ragan, I.; Westphal, M. Consensus document
on european brain research. J. Neurol. Neurosurg. Psychiatry 2006, 77 (Suppl. 1), 1–49.
2. Pardridge, W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2005, 2, 3–14.
[CrossRef] [PubMed]
3. Wolburg, H.; Lippoldt, A. Tight junctions of the blood-brain barrier: Development, composition and
regulation. Vasc. Pharmacol. 2002, 38, 323–337. [CrossRef]
4. Alavijeh, M.S.; Chishty, M.; Qaiser, M.Z.; Palmer, A.M. Drug metabolism and pharmacokinetics, the
blood-brain barrier, and central nervous system drug discovery. NeuroRX 2005, 2, 554–571. [CrossRef]
[PubMed]
5. Feher, M.; Sourial, E.; Schmidt, J.M. A simple model for the prediction of blood-brain partitioning.
Int. J. Pharm. 2000, 201, 239–247. [CrossRef]
6. Vilar, S.; Chakrabarti, M.; Costanzi, S. Prediction of passive blood-brain partitioning: Straightforward and
effective classification models based on in silico derived physicochemical descriptors. J. Mol. Graph. Model.
2010, 28, 899–903. [CrossRef] [PubMed]
7. Jeffrey, P.; Summerfield, S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol. Dis.
2010, 37, 33–37. [CrossRef] [PubMed]
8. Smith, D.A.; Di, L.; Kerns, E.H. The effect of plasma protein binding on in vivo efficacy: Misconceptions in
drug discovery. Nat. Rev. Drug Discov. 2010, 9, 929–939. [CrossRef] [PubMed]
9. Elmquist, W.F.; Sawchuk, R.J. Application of microdialysis in pharmacokinetic studies. Pharm. Res. 1997, 14,
267–288. [CrossRef] [PubMed]
10. Hammarlund-Udenaes, M.; Paalzow, L.K.; de Lange, E.C. Drug equilibration across the blood-brain
barrier–pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 1997, 14, 128–134.
[CrossRef] [PubMed]
11. Brown, R.P.; Delp, M.D.; Lindstedt, S.L.; Rhomberg, L.R.; Beliles, R.P. Physiological parameter values for
physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13, 407–484. [CrossRef] [PubMed]
12. Kalvass, J.C.; Maurer, T.S. Influence of nonspecific brain and plasma binding on CNS exposure: Implications
for rational drug discovery. Biopharm. Drug Dispos. 2002, 23, 327–338. [CrossRef] [PubMed]
13. Doran, A.; Obach, R.S.; Smith, B.J.; Hosea, N.A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.;
Cianfrogna, J.; et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the
central nervous system: Evaluation using the mdr1a/1b knockout mouse model. Drug Metab. Dispos. 2005,
33, 165–174. [CrossRef] [PubMed]
14. Liu, X.; Smith, B.J.; Chen, C.; Callegari, E.; Becker, S.L.; Chen, X.; Cianfrogna, J.; Doran, A.C.; Doran, S.D.;
Gibbs, J.P.; et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate
measurement for brain free concentration. Drug Metab. Dispos. 2006, 34, 1443–1447. [CrossRef] [PubMed]
15. Becker, S.; Liu, X.R. Evaluation of the utility of brain slice methods to study brain penetration.
Drug Metab. Dispos. 2006, 34, 855–861. [CrossRef] [PubMed]
16. Summerfield, S.G.; Stevens, A.J.; Cutler, L.; Osuna, M.D.; Hammond, B.; Tang, S.P.; Hersey, A.; Spalding, D.J.;
Jeffrey, P. Improving the in vitro prediction of in vivo central nervous system penetration: Integrating
permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 2006, 316,
1282–1290. [CrossRef] [PubMed]
17. Summerfield, S.G.; Read, K.; Begley, D.J.; Obradovic, T.; Hidalgo, I.J.; Coggon, S.; Lewis, A.V.; Porter, R.A.;
Jeffrey, P. Central nervous system drug disposition: The relationship between in situ brain permeability and
brain free fraction. J. Pharmacol. Exp. Ther. 2007, 322, 205–213. [CrossRef] [PubMed]
18. Summerfield, S.G.; Lucas, A.J.; Porter, R.A.; Jeffrey, P.; Gunn, R.N.; Read, K.R.; Stevens, A.J.; Metcalf, A.C.;
Osuna, M.C.; Kilford, P.J.; et al. Toward an improved prediction of human in vivo brain penetration.
Xenobiotica 2008, 38, 1518–1535. [CrossRef] [PubMed]
19. Kim, C.S.; Sandberg, J.A.; Slikker, W.; Binienda, Z.; Schlosser, P.M.; Patterson, T.A. Quantitative exposure
assessment: Application of physiologically-based pharmacokinetic (PBPK) modeling of low-dose, long-term
exposures of organic acid toxicant in the brain. Environ. Toxicol. Pharmacol. 2001, 9, 153–160. [CrossRef]
Pharmaceutics 2018, 10, 14 16 of 18
20. Yamamoto, Y.; Välitalo, P.A.; Wong, Y.C.; Huntjens, D.R.; Proost, J.H.; Vermeulen, A.; Krauwinkel, W.;
Beukers, M.W.; Kokki, H.; Kokki, M.; et al. Prediction of human CNS pharmacokinetics using a
physiologically-based pharmacokinetic modeling approach. Eur. J. Pharm. Sci. 2018, 112, 168–179. [CrossRef]
[PubMed]
21. Yamamoto, Y.; Välitalo, P.A.; van den Berg, D.-J.; Hartman, R.; van den Brink, W.; Wong, Y.C.; Huntjens, D.R.;
Proost, J.H.; Vermeulen, A.; Krauwinkel, W.; et al. A generic multi-compartmental CNS distribution model
structure for 9 drugs allows prediction of human brain target site concentrations. Pharm. Res. 2017, 34,
333–351. [CrossRef] [PubMed]
22. Yamamoto, Y.; Välitalo, P.A.; Huntjens, D.R.; Proost, J.H.; Vermeulen, A.; Krauwinkel, W.; Beukers, M.W.;
van den Berg, D.-J.; Hartman, R.; Wong, Y.C.; et al. Predicting drug concentration-time profiles in multiple
CNS compartments using a comprehensive physiologically-based pharmacokinetic model. CPT Pharmacomet.
Syst. Pharmacol. 2017, 6, 765–777. [CrossRef] [PubMed]
23. Yamamoto, Y.; Danhof, M.; de Lange, E.C.M. Microdialysis: The key to physiologically based model
prediction of human CNS target site concentrations. AAPS J. 2017, 19, 891–909. [CrossRef] [PubMed]
24. Beal, S.; Sheiner, L.; Boeckmann, A.; Bauer, R. NonmemUser’s Guides (1989–2009); Icon Development Solutions:
Ellicott City, MD, USA, 2009.
25. Campbell, J.; Van Landingham, C.; Crowell, S.; Gentry, R.; Kaden, D.; Fiebelkorn, S.; Loccisano, A.; Clewell, H.
A preliminary regional PBPK model of lung metabolism for improving species dependent descriptions of
1,3-butadiene and its metabolites. Chem.-Biol. Interact. 2015, 238, 102–110. [CrossRef] [PubMed]
26. Neuhoff, S.; Gaohua, L.; Burt, H.; Jamei, M.; Li, L.; Tucker, G.T.; Rostami-Hodjegan, A. Accounting for
transporters in renal clearance: Towards a mechanistic kidney model (Mech Kim). In Transporters in Drug
Development: Discovery, Optimization, Clinical Study and Regulation; Sugiyama, Y., Steffansen, B., Eds.; Springer:
New York, NY, USA, 2013; pp. 155–177.
27. Jamei, M.; Turner, D.; Yang, J.; Neuhoff, S.; Polak, S.; Rostami-Hodjegan, A.; Tucker, G. Population-based
mechanistic prediction of oral drug absorption. AAPS J. 2009, 11, 225–237. [CrossRef] [PubMed]
28. Badhan, R.K.S.; Chenel, M.; Penny, J.I. Development of a physiologically-based pharmacokinetic model of
the rat central nervous system. Pharmaceutics 2014, 6, 97–136. [CrossRef] [PubMed]
29. Ball, K.; Bouzom, F.; Scherrmann, J.M.; Walther, B.; Decleves, X. A physiologically based modeling strategy
during preclinical CNS drug development. Mol. Pharm. 2014, 11, 836–848. [CrossRef] [PubMed]
30. Ball, K.; Bouzom, F.; Scherrmann, J.-M.; Walther, B.; Declèves, X. Development of a physiologically
based pharmacokinetic model for the rat central nervous system and determination of an in vitro–in vivo
scaling methodology for the blood–brain barrier permeability of two transporter substrates, morphine and
oxycodone. J. Pharm. Sci. 2012, 101, 4277–4292. [CrossRef] [PubMed]
31. Walker, M.C.; Alavijeh, M.S.; Shorvon, S.D.; Patsalos, P.N. Microdialysis study of the neuropharmacokinetics
of phenytoin in rat hippocampus and frontal cortex. Epilepsia 1996, 37, 421–427. [CrossRef] [PubMed]
32. Sechi, G.P.; Petruzzi, V.; Rosati, G.; Tanca, S.; Monaco, F.; Formato, M.; Rubattu, L.; Deriu, P. Brain interstitial
fluid and intracellular-distribution of phenytoin. Epilepsia 1989, 30, 235–239. [CrossRef] [PubMed]
33. Van Belle, K.; Sarre, S.; Ebinger, G.; Michotte, Y. Brain, liver and blood distribution kinetics of carbamazepine
and its metabolic interaction with clomipramine in rats: A quantitative microdialysis study. J. Pharmacol.
Exp. Ther. 1995, 272, 1217–1222. [PubMed]
34. Bouw, R.; Ederoth, P.; Lundberg, J.; Ungerstedt, U.; Nordström, C.H.; Hammarlund-Udenaes, M. Increased
blood–brain barrier permeability of morphine in a patient with severe brain lesions as determined by
microdialysis. Acta Anaesthesiol. Scand. 2001, 45, 390–392. [CrossRef] [PubMed]
35. Ederoth, P.; Tunblad, K.; Bouw, R.; Lundberg, C.J.F.; Ungerstedt, U.; Nordström, C.-H.; Hammarlund-Udenaes, M.
Blood–brain barrier transport of morphine in patients with severe brain trauma. Br. J. Clin. Pharmacol. 2004,
57, 427–435. [CrossRef] [PubMed]
36. Matalab 2016b; The MathWorks Inc.: Natick, MA, USA.
37. Lin, J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics.
Drug Metab. Dispos. 1998, 26, 1202–1212. [PubMed]
38. Houston, J.B. Utility of in-vitro drug-metabolism data in predicting in-vivo metabolic-clearance.
Biochem. Pharmacol. 1994, 47, 1469–1479. [CrossRef]
Pharmaceutics 2018, 10, 14 17 of 18
39. Naritomi, Y.; Terashita, S.; Kimura, S.; Suzuki, A.; Kagayama, A.; Sugiyama, Y. Prediction of human hepatic
clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from
animals and humans. Drug Metab. Dispos. 2001, 29, 1316–1324. [PubMed]
40. Iwatsubo, T.; Suzuki, H.; Shimada, N.; Chiba, K.; Ishizaki, T.; Green, C.E.; Tyson, C.A.; Yokoi, T.; Kamataki, T.;
Sugiyama, Y. Prediction of in vivo hepatic metabolic clearance of ym796 from in vitro data by use of human
liver microsomes and recombinant p-450 isozymes. J. Pharmacol. Exp. Ther. 1997, 282, 909–919. [PubMed]
41. Poulin, P.; Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically
based pharmacokinetic models of drug disposition. J. Pharm. Sci. 2002, 91, 1358–1370. [CrossRef] [PubMed]
42. Hammarlund-Udenaes, M.; Friden, M.; Syvanen, S.; Gupta, A. On the rate and extent of drug delivery to the
brain. Pharm. Res. 2008, 25, 1737–1750. [CrossRef] [PubMed]
43. Pardridge, W.M. Drug and gene delivery to the brain: The vascular route. Neuron 2002, 36, 555–558.
[CrossRef]
44. Davies, B.; Morris, T. Physiological-parameters in laboratory-animals and humans. Pharm. Res. 1993, 10,
1093–1095. [CrossRef] [PubMed]
45. Spanswick, S.C.; Dyck, R.H. Object/context specific memory deficits following medial frontal cortex damage
in mice. PLoS ONE 2012, 7, 1–7. [CrossRef] [PubMed]
46. Ashbrook, D.G.; Williams, R.W.; Lu, L.; Stein, J.L.; Hibar, D.P.; Nichols, T.E.; Medland, S.E.; Thompson, P.M.;
Hager, R. Joint genetic analysis of hippocampal size in mouse and human identifies a novel gene linked to
neurodegenerative disease. BMC Genom. 2014, 15, 1–9. [CrossRef] [PubMed]
47. Hong, L.; Jiang, W.; Pan, H.; Jiang, Y.; Zeng, S.; Zheng, W. Brain regional pharmacokinetics of P-aminosalicylic
acid and its n-acetylated metabolite: Effectiveness in chelating brain manganese. Drug Metab. Dispos. 2011,
39, 1904–1909. [CrossRef] [PubMed]
48. Syková, E.; Nicholson, C. Diffusion in brain extracellular space. Physiol. Rev. 2008, 88, 1277–1340. [CrossRef]
[PubMed]
49. Murtha, L.A.; Yang, Q.; Parsons, M.W.; Levi, C.R.; Beard, D.J.; Spratt, N.J.; McLeod, D.D. Cerebrospinal fluid
is drained primarily via the spinal canal and olfactory route in young and aged spontaneously hypertensive
rats. Fluids Barriers CNS 2014, 11, 12. [CrossRef] [PubMed]
50. Hamberger, A.; Jacobson, I.; NystrÖM, B.; Sandberg, M. Microdialysis sampling of the neuronal environment
in basic and clinical research. J. Intern. Med. 1991, 230, 375–380. [CrossRef] [PubMed]
51. Poulin, P.; Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction
of volume of distribution. J. Pharm. Sci. 2002, 91, 129–156. [CrossRef] [PubMed]
52. Abbott, N.J. Evidence for bulk flow of brain interstitial fluid: Significance for physiology and pathology.
Neurochem. Int. 2004, 45, 545–552. [CrossRef] [PubMed]
53. Harnish, P.P.; Samuel, K. Reduced cerebrospinal-fluid production in the rat and rabbit by diatrizoate
ventriculocisternal perfusion. Investig. Radiol. 1988, 23, 534–536. [CrossRef]
54. Brinker, T.; Stopa, E.; Morrison, J.; Klinge, P. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS
2014, 11, 10. [CrossRef] [PubMed]
55. Lu, G.; Neuhoff, S.; Johnson, T.N.; Rostami-Hodjegan, A.; Jamei, M. Development of a permeability-limited
model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological
knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro edata.
Drug Metab. Pharmacokinet. 2016, 31, 224–233.
56. Meno-Tetang, G.M.; Li, H.; Mis, S.; Pyszczynski, N.; Heining, P.; Lowe, P.; Jusko, W.J. Physiologically based
pharmacokinetic modeling of fty720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in
rats after oral and intravenous doses. Drug Metab. Dispos. 2006, 34, 1480–1487. [CrossRef] [PubMed]
57. Lee, T.; Jarome, T.; Li, S.-J.; Kim, J.J.; Helmstetter, F.J. Chronic stress selectively reduces hippocampal volume
in rats: A longitudinal mri study. Neuroreport 2009, 20, 1554–1558. [CrossRef] [PubMed]
58. Honeycutt, N.A.; Smith, C.D. Hippocampal volume measurements using magnetic resonance imaging in
normal young adults. J. Neuroimaging 1995, 5, 95–100. [CrossRef] [PubMed]
59. Dexter, B.C.; Rahmouni, K.; Cushman, T.; Hermann, G.M.; Ni, C.; Nopoulos, P.C.; Thedens, D.L.; Roghair, R.D.
Neonatal leptin deficiency reduces frontal cortex volumes and programs adult hyperactivity in mice.
Behav. Brain Res. 2014, 263, 115–121. [CrossRef] [PubMed]
60. Semendeferi, K.; Lu, A.; Schenker, N.; Damasio, H. Humans and great apes share a large frontal cortex.
Nat. Neurosci. 2002, 5, 272–276. [CrossRef] [PubMed]
Pharmaceutics 2018, 10, 14 18 of 18
61. Bass, N.H.; Lundborg, P. Postnatal development of bulk flow in the cerebrospinal fluid system of the albino
rat: Clearance of carboxyl-[14C]inulin after intrathecal infusion. Brain Res. 1973, 52, 323–332. [CrossRef]
62. Sakka, L.; Coll, G.; Chazal, J. Anatomy and physiology of cerebrospinal fluid. Eur. Ann. Otorhinolaryngol.
Head Neck Dis. 2011, 128, 309–316. [CrossRef] [PubMed]
63. Reichel, A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr. Drug Metab. 2006, 7,
183–203. [CrossRef] [PubMed]
64. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: Predicting the
tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005, 94, 1259–1276. [CrossRef] [PubMed]
65. Tornqvist, E.; Annas, A.; Granath, B.; Jalkesten, E.; Cotgreave, I.; Oberg, M. Strategic focus on 3r principles
reveals major reductions in the use of animals in pharmaceutical toxicity testing. PLoS ONE 2014, 9, 1–11.
[CrossRef] [PubMed]
66. Suzuki, H.; Sawada, Y.; Sugiyama, Y.; Iga, T.; Hanano, M. Facilitated transport of benzylpenicillin through
the blood-brain barrier in rats. J. Pharmacobio-Dyn. 1989, 12, 182–185. [CrossRef] [PubMed]
67. Suzuki, H.; Terasaki, T.; Sugiyama, Y. Role of efflux transport across the blood-brain barrier and blood
cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug
Deliv. Rev. 1997, 25, 257–285. [CrossRef]
68. Dahlström, B.E.; Paalzow, L.K. Pharmacokinetics of morphine in plasma and discrete areas of the rat brain.
J. Pharmacokinet. Biopharm. 1975, 3, 293–302. [CrossRef] [PubMed]
69. Yokagawa, K.; Nakashima, E.; Ishizaki, J.; Hasegawa, M.; Kido, H.; Ichimura, F. Brain regional
pharmacokinetics of biperiden in rats. Biopharm. Drug Dispos. 1992, 13, 131–140. [CrossRef]
70. Kamiie, J.; Ohtsuki, S.; Iwase, R.; Ohmine, K.; Katsukura, Y.; Yanai, K.; Sekine, Y.; Uchida, Y.; Ito, S.; Terasaki, T.
Quantitative atlas of membrane transporter proteins: Development and application of a highly sensitive
simultaneous lc/ms/ms method combined with novel in-silico peptide selection criteria. Pharm. Res. 2008,
25, 1469–1483. [CrossRef] [PubMed]
71. Hoshi, Y.; Uchida, Y.; Tachikawa, M.; Inoue, T.; Ohtsuki, S.; Terasaki, T. Quantitative atlas of blood-brain
barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. 2013,
102, 3343–3355. [CrossRef] [PubMed]
72. Adachi, Y.; Suzuki, H.; Sugiyama, Y. Comparative studies on in vitro methods for evaluating in vivo function
of mdr1 P-glycoprotein. Pharm. Res. 2001, 18, 1660–1668. [CrossRef] [PubMed]
73. Uchida, Y.; Ohtsuki, S.; Kamiie, J.; Terasaki, T. Blood-brain barrier (BBB) pharmacoproteomics: Reconstruction
of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein
concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
J. Pharmacol. Exp. Ther. 2011, 339, 579–588. [PubMed]
74. O’Brien, J.S.; Sampson, E.L. Lipid composition of the normal human brain: Gray matter, white matter,
and myelin. J. Lipid Res. 1965, 6, 537–544. [PubMed]
75. O’Brien, J.S.; Sampson, E.L. Fatty acid and fatty aldehyde composition of the major brain lipids in normal
human gray matter, white matter, and myelin. J. Lipid Res. 1965, 6, 545–551. [PubMed]
76. Lohmann, C.; Schachmann, E.; Dandekar, T.; Villmann, C.; Becker, C.M. Developmental profiling by mass
spectrometry of phosphocholine containing phospholipids in the rat nervous system reveals temporo-spatial
gradients. J. Neurochem. 2010, 114, 1119–1134. [CrossRef] [PubMed]
77. Martinez, M.; Mougan, I. Fatty acid composition of human brain phospholipids during normal development.
J. Neurochem. 1998, 71, 2528–2533. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
